Logo
Paradigm Biopharmaceuticals

Inflammatory Arthritis

Persistent inflammation, pain and structural joint damage remain significant challenges across a range of arthritic conditions, despite existing treatment options.

Paradigm’s work in this area includes injectable pentosan polysulfate sodium for alphavirus-induced arthralgia, supported by a completed and published Ross River virus study and preclinical research in chikungunya virus-infected mice. The portfolio also includes Pentacoxib™, an oral combination therapy licensed to AVet Health for veterinary osteoarthritis in Australia and New Zealand.

Development overview

Paradigm holds exclusive worldwide rights to commercialise pentosan polysulfate sodium (PPS) for alphavirus-induced arthritis and joint pain, under a licence from the Institute for Glycomics at Griffith University announced in September 2016. Paradigm has subsequently secured relevant patent protection across key global markets.

The alphavirus programme includes clinical and preclinical development across two indications. In Ross River virus, Paradigm completed a Phase 2a randomised, double-blind, placebo-controlled pilot study of injectable PPS, with results subsequently published. In chikungunya, development remains preclinical, supported by studies in chikungunya virus-infected mice.

Paradigm has also acquired intellectual property and early human data relating to a combination product developed by Professor Peter Ghosh. The early clinical work evaluated the combination in people with osteoarthritis and provides the foundation for Pentacoxib™, Paradigm’s oral PPS and COX-2 inhibitor combination.

Participants randomised 20 Thirteen received PPS and seven received placebo in the Ross River virus study (Krishnan et al., 2021).
Registered clinical study 1 ACTRN12617000893303 on the Australian New Zealand Clinical Trials Registry. Recruitment status: completed.
Peer-reviewed publications 2 BMC Musculoskeletal Disorders (2021) for Ross River virus and PLOS ONE (2021) for the chikungunya mouse study.

Ross River virus · persistent RRV-induced arthralgia

Status
Complete and not recruiting. The only current route referenced for PPS in this indication is compassionate access
Registry
ACTRN12617000893303 (ANZCTR)
Design
Phase 2a randomised, double-blind, placebo-controlled pilot study of injectable PPS; 20 participants randomised, 13 to PPS and 7 to placebo
Dates
25 July 2017 to 5 November 2018
Publication
Krishnan et al., BMC Musculoskeletal Disorders (2021) 22:271

Chikungunya

Status
Preclinical
Model
Chikungunya virus-infected mice
Clinical studies
None conducted to date
Publication
Rudd et al., PLOS ONE (2021)

Pentacoxib™

Status
Early development
Stage
Human proof of concept
Clinical evidence
Early double-blind comparator study completed in hand and knee osteoarthritis

Milestones

The milestones below reflect the development history across Paradigm’s alphavirus and Pentacoxib™ programs. No further clinical development milestone is currently guided for Ross River virus or chikungunya.

  1. SEP 2016 Paradigm secured exclusive worldwide rights from the Institute for Glycomics at Griffith University to commercialise PPS for alphavirus-induced arthritis and joint pain. COMPLETE
  2. JUL 2017 Phase 2a Ross River virus study, ACTRN12617000893303, commenced. COMPLETE
  3. 2018–2019 Early human proof-of-concept studies evaluated an oral combination of PPS and celecoxib in patients with hand and knee osteoarthritis, providing the clinical foundation for the product now known as Pentacoxib™. COMPLETE
  4. NOV 2018 Ross River virus Phase 2a pilot study concluded. COMPLETE
  5. MAR 2021 Results from the Phase 2a Ross River virus study were published in BMC Musculoskeletal Disorders. COMPLETE
  6. SEP 2021 Preclinical research evaluating PPS in chikungunya virus-infected mice was published in PLOS ONE. COMPLETE
  7. JUN 2025 Paradigm acquired Proteobioactives, securing the intellectual property, formulation know-how and global development and commercialisation rights associated with Pentacoxib™. COMPLETE

Facts Box

  • CHIKV

    Potentially affecting over 1 billion people 13

  • CHIKV

    Patients who suffer musculoskeletal manifestations of CHIKV - ≥ 95% 13

  • CHIKV

    CHIKV patients with arthralgia: as high as 43 % at 12 months declining to 13 % at 3 years 7-8

  • RRV

    On average 5000 cases in Australia per year

    (http://www9.health.gov.au/cda/source/rpt_3.cfm)

  • RRV

    Patients who suffer musculoskeletal manifestations of RRV - ≥95% 2

  • RRV

    RRV patients with arthralgia: 11 % at 3 months and 5 % at 4 years 9

Where to go from here

If you or someone you care for is living with persistent joint pain after a Ross River virus or chikungunya infection, Paradigm’s Ross River virus study concluded in November 2018 and there is no open study in either indication. Paradigm is not able to discuss an individual’s eligibility for a clinical trial, or any matter relating to your condition. Your own doctor or rheumatologist is the right person to talk to about your care.

For investors and potential partners: Pentacoxib™ is licensed to AVet Health for veterinary osteoarthritis in Australia and New Zealand, and human development of the combination has not commenced. Announcements and disclosures are published in full on this hub.

Injectable pentosan polysulfate sodium is an investigational medicine in alphavirus-induced arthralgia and in inflammatory arthritis. It is not approved for either indication in any jurisdiction and is not available outside a clinical trial or an authorised access scheme. Pentacoxib™ is an investigational oral combination: it is in development for veterinary use and is not yet registered, and it is not approved for human use. Nothing on this page is medical or veterinary advice, or an offer of treatment.